WallStSmart
CRNX

Crinetics Pharmaceuticals Inc

NASDAQ: CRNX · HEALTHCARE · BIOTECHNOLOGY

$38.78
+0.88% today

Updated 2026-04-30

Market cap
$3.99B
P/E ratio
P/S ratio
519.04x
EPS (TTM)
$-4.95
Dividend yield
52W range
$26 – $58
Volume
1.1M

Crinetics Pharmaceuticals Inc (CRNX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2016201720182019202020212022202320242025
Revenue$589000.00$2.04M$2.43M$1.19M$71000.00$1.08M$4.74M$4.01M$1.04M$7.70M
Revenue growth (YoY)+247.2%+18.7%-50.9%-94.0%+1418.3%+339.4%-15.3%-74.1%+640.7%
Cost of revenue$5.10M$9.23M$24.48M$41.51M$57.00M$1.26M$1.39M$1.10M$2.79M$4.97M
Gross profit$-4.51M$-7.19M$2.43M$1.19M$71000.00$1.08M$4.74M$4.01M$1.04M$2.73M
Gross margin-765.9%-351.5%100.0%100.0%100.0%100.0%100.0%100.0%100.0%35.5%
R&D$5.10M$9.23M$24.48M$41.51M$57.00M$84.25M$130.22M$168.53M$240.16M$332.06M
SG&A$1.53M$1.94M$6.66M$13.52M$18.03M$24.52M$42.39M$58.09M$99.74M$191.33M
Operating income$-6.04M$-9.13M$-28.71M$-53.83M$-74.95M$-107.70M$-167.88M$-222.61M$-338.85M$-516.77M
Operating margin-1026.1%-446.3%-1182.5%-4512.3%-105567.6%-9990.9%-3544.1%-5547.2%-32613.5%-6714.8%
EBITDA$-5.95M$-9.00M$-28.24M$-52.95M$-74.00M$-106.78M$-166.90M$-221.51M$-336.07M$-461.25M
EBITDA margin-1010.5%-440.0%-1163.1%-4438.0%-104232.4%-9905.4%-3523.3%-5519.8%-32345.4%-5993.3%
EBIT$-6.04M$-9.13M$-28.71M$-53.83M$-74.95M$-107.70M$-167.88M$-222.61M$-338.85M$-465.14M
Interest expense$11000.00$8000.00$0.00$0.00$991000.00$61000.00$4.32M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-6.02M$-9.16M$-27.11M$-49.53M$-72.86M$-106.72M$-159.95M$-214.53M$-298.41M$-465.32M
Net income growth (YoY)-52.1%-196.1%-82.7%-47.1%-46.5%-49.9%-34.1%-39.1%-55.9%
Profit margin-1021.9%-447.8%-1116.8%-4152.1%-102625.4%-9899.7%-3376.7%-5345.9%-28720.7%-6046.2%